Wells Fargo & Company Recursion Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$187 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$144 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$138 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$98.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$87.7 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.03B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...